Idera Pharmaceuticals is a biopharmaceutical company. The company utilizes two proprietary drug discovery technology platforms to design and develop drug candidates: Toll-like receptor (TLR); and its nucleic acid. The company's TLR drug candidates are: IMO-2125, an indication for Anti-PD1 Refractory Metastatic Melanoma and Refractory Solid Tumors; and IMO-8400, an indication for Dermatomyositis. The company's Nucleic Acid Chemistry research programs comprised of: IDRA-008, for treatment of Familial Chylomicronemia Syndrome and Familial Partial Lipodystrophy; Nucleic Acid Chemistry Compound, an indication for renal disease; and IMO-9200, an indication for non-malignant Gastrointestinal Disorders.
- ExchangeNASDAQ Stock Market
- SectorPharmaceuticals & Biotechnology
- CountryUnited States